Literature DB >> 16531922

Radioactive iodine treatment in medullary thyroid carcinoma.

Murat Faik Erdogan1, Alptekin Gursoy, Gurbuz Erdogan, Nuri Kamel.   

Abstract

BACKGROUND: Elevated levels of basal and stimulated calcitonin are commonly seen in hereditary and sporadic medullary thyroid cancer (MTC) following total thyroidectomy. The cause of these high levels can be residual thyroid tissue, possibly with C-cell hyperplasia, and/or residual micro-MTC foci. MTC does not have the ability to concentrate radioactive iodine. However, radioactive iodine trapped by thyroid follicular cells may affect the neighbouring parafollicular cells. AIM: To investigate the effect of radioactive iodine treatment as adjuvant therapy to surgery in seven patients with persistent elevation of basal and stimulated calcitonin levels.
METHODS: Pentagastrin testing was performed in each case immediately before surgery and at intervals of 6 months over a maximum period of 5 years (range, 44-60 months) after surgery.
RESULTS: A significant decrease in basal and stimulated calcitonin levels was observed in three patients whose disease was localized to the thyroid gland at the final visit. In the remaining four patients, who initially had lymph node involvement at surgery, basal and stimulated calcitonin levels were decreased significantly in only one. At follow-up, of the three patients who showed no decrease in basal and stimulated calcitonin levels, two developed further regional lymph node and distant metastases.
CONCLUSIONS: In patients with persistently elevated basal and stimulated calcitonin levels, radioactive iodine treatment may be the therapy of choice for C-cell hyperplasia and/or micro-MTC after optimal thyroid surgery, especially if the disease has not spread beyond the thyroid gland.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16531922     DOI: 10.1097/01.mnm.0000202860.30274.e4

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  7 in total

Review 1.  Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine.

Authors:  Antonio Matrone; Carla Gambale; Alessandro Prete; Rossella Elisei
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-29       Impact factor: 6.055

2.  Prognostic and predictive markers in medullary thyroid carcinoma.

Authors:  Boban M Erovic; Dae Kim; Clarissa Cassol; David P Goldstein; Jonathan C Irish; Sylvia L Asa; Ozgur Mete
Journal:  Endocr Pathol       Date:  2012-12       Impact factor: 3.943

Review 3.  Medical management of metastatic medullary thyroid cancer.

Authors:  Jessica E Maxwell; Scott K Sherman; Thomas M O'Dorisio; James R Howe
Journal:  Cancer       Date:  2014-06-18       Impact factor: 6.860

4.  Utility of serum thyroglobulin measurements after prophylactic thyroidectomy in patients with hereditary medullary thyroid cancer.

Authors:  Carolyn D Seib; Avital Harari; Felix A Conte; Quan-Yang Duh; Orlo H Clark; Jessica E Gosnell
Journal:  Surgery       Date:  2014-06-02       Impact factor: 3.982

Review 5.  Evidence-based approach to the management of sporadic medullary thyroid carcinoma.

Authors:  Jeffrey F Moley; Elizabeth A Fialkowski
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

6.  Recurrent spinal metastasis of a sporadic medullary carcinoma of the thyroid after radiation therapy: a case report and review of the literature.

Authors:  Christopher Munoz-Bendix; Antonio Santacroce; Kristin Gierga; Frank W Floeth; Hans-Jakob Steiger; Marco Antonio Penalonzo; Sven Oliver Eicker
Journal:  Clin Case Rep       Date:  2015-11-09

7.  Trends in the Diagnosis and Treatment of Patients with Medullary Thyroid Carcinoma in Korea.

Authors:  Hwa Young Ahn; Jae Eun Chae; Hyemi Moon; Junghyun Noh; Young Joo Park; Sin Gon Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2020-11-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.